Senior Clinical Program Manager

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

Requirements

• Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines.
• Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed.
• Actively contribute in the selection and management of contract research organizations (CROs) and/or vendors, including development of requests for proposals (RFPs).
• Lead Clinical Study Execution Team (CSETs) and influence relevant stakeholders both internally and externally including management.
• May lead interdepartmental strategic business initiatives as well as spearhead certain SOP development and training.

Benefits

• Generous Paid Time Off
• 401k Matching
• Retirement Plan
• Robust equity awards
• Significant learning and development opportunities